First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Medications used for the treatment of type 2 diabetes
Slide 40
Class
HbA1c
change
Hypoglycae- Weight
mia risk
change
Metformin
1.5
No
Neutral
Sulfonylurea
1.5
Yes
Gain
Commonly prescribed product classes for the treatment of type 2 diabetes
Contraindication/
undesired effects
Kidney, liver
Essentially none
CVD risk
Dosing
(pr. day)
Minimal
2 OADs
None
1 OAD
TZDS
0.5-1.4
No
Gain
Varies
1 OAD
DPP-IV inhibitors
0.6 -0.8
No
Neutral
TBD
1-2 OADs
CHF, liver
None
SGLT-2 inhibitors
0.5 -0.9
No
Loss
GLP-1
1.0 - 2.0
No
Loss
Long-acting insulin
1.5-2.5
Yes
Gain
Fast-acting insulin
1.5-2.5
Yes
Gain
Genital infections, urinary
tract infections
GI side effects, MTC
Hypoglycaemia
Hypoglycaemia
Note: TG and HDL: Beneficial effect on triglycerides and high-density lipoprotein cholesterol; CHF: Congestive heart failure; GI: Gastro intestinal; MTC: Medullary thyroid cancer; TZD: thiazolidinediones;
OAD: Oral anti-diabetic; TBD: to be defined.
Sources: Adapted from: Nathan DM, et al. Diabetes Care. 2006; 29:1963-1972; Nathan DM, et al. Diabetes Care. 2007;30:753-759; Nathan DM, et al. Diabetes Care. 2008;31:173-175. ADA. Diabetes
Care. 2008;31:S12-S54. Wel Chol PI. 1/2008.
Varies
1 OAD
Varies
Varies
TG and HDL
TG and HDL
1 injection
1-4 injections
changing
diabetes®
novo nordiskView entire presentation